Following PD-1 and car-t, there is a global upsurge of research on protac drugs. The research and development of portac drugs in China is also in full swing. From the public information, more than 10 companies have laid out protac technology, and a total of 5 domestic protac innovative drugs have entered the clinical stage.
According to the monitoring of people’s finance · innovative drug database, during the new release cycle from February 11 to February 17, Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) sal0114 tablets, Tianjing biological thz0106 injection, Shandong Buchang Pharmaceuticals Co.Ltd(603858) bc0305 capsule and other 13 innovative drugs were approved clinically for the first time in China. At the same time, Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) focused on the research and innovation of new drugs, eugliptin tablets The R & D Progress of potential heavy varieties of Chongqing Zhifei Biological Products Co.Ltd(300122) and recombinant tuberculosis vaccine is advancing.
Driven by these factors, the “people’s finance · innovative drug index” Rose 1.12% to 2407.21 points in the new release cycle.
Protac, fully known as protein degradation targeted chimera. Compared with traditional small molecule drugs, protein degrading agents based on protac have unique advantages. Among them, one of the biggest advantages is that it can target the target or mutant protein that is difficult to be made into medicine. Research shows that at present, the target of drug development is less than 20%, and up to 80% of protein targets can not be intervened by traditional drug research and development methods. In addition, protac molecule can degrade the target protein without long-term binding with the target protein to completely eliminate its function, which is expected to solve the drug resistance problem of small molecule inhibitors.
At present, there is no protac drug approved for listing in the world. The star company arvinas is the first company to enter this field, and its two protac drugs arv-110 and arv-471 are in phase II clinical practice. On February 14, arvinas announced that arv-110 continued to show evidence of antitumor activity and patient benefit in clinical trials. The company plans to launch key clinical trials of arv-110 within this year. It means that the world’s first protac drug is one step closer to being approved.
In recent years, Roche, Pfizer, Bayer, MSD, GSK, Novartis, AstraZeneca and other pharmaceutical giants have stepped up the field of protac.
Haisco Pharmaceutical Group Co.Ltd(002653) is the first company in China to submit the clinical application of protac drugs. Its developed hsk29116 is an oral protac small molecule antitumor drug targeting Btk. It was approved for clinical trial in April last year for the treatment of recurrent and refractory B-cell lymphoma. Previously, Haisco Pharmaceutical Group Co.Ltd(002653) said on the investor interaction platform that the company has explored protac technology for more than three years. So far, it has arranged more than 10 early projects and submitted more than 30 patents.
China’s second approved clinical protac drug is the protac-ar degradation agent gt20029, which develops the pharmaceutical industry. In April and July last year, it was approved by the State Food and Drug Administration and the FDA to carry out clinical trials for the treatment of androgenic alopecia and acne. This month, gt20029 US phase I clinical trial completed the administration of the first subject.
At the end of last year, bgb-16673 of Baiji Shenzhou was approved by the State Food and drug administration. This is the second btk-protac approved for clinical use in China after hsk29116. It is also the first product developed by Baiji Shenzhou based on its protein degradation CDAC technology platform and entered the clinical stage.
Iceland spar biological ac0682 is an oral bioavailable protac designed to target and degrade er with high potency and selectivity α The protein was approved by FDA in September last year for clinical trials to treat estrogen receptor positive breast cancer. The China clinical trial application was received by CDE last month.
Haichuang Pharmaceutical Co., Ltd. is also an earlier enterprise in China to carry out the research and development of protac technology. On January 19, the protac-ar degrading agent hp518 independently developed by Haichuang pharmaceutical achieved the first patient administration in the phase I clinical trial in Australia. According to the prospectus of Haichuang pharmaceutical, the company has synthesized multiple target protein ligands and hundreds of linkers, and has rich experience in protac molecular structure design and compound synthesis.
In addition, Jiangsu Hengrui Medicine Co.Ltd(600276) and Shiyao group have established the protac platform, and the drugs developed by Lingke pharmaceutical, Yasheng pharmaceutical and Nuo Chengjianhua are in the preclinical research stage; Cro companies such as Wuxi Apptec Co.Ltd(603259) , Shanghai Medicilon Inc(688202) are also increasing the layout of praotc technology.
During the new release cycle from February 11 to February 17, the research and development of innovative drugs in China continued to advance steadily. 13 innovative drugs such as sal0114 tablet of Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) , thz0106 injection of Tianjing biology and bc0305 capsule of Shandong Buchang Pharmaceuticals Co.Ltd(603858) have been approved for clinical use for the first time in China. At the same time, Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) focuses on the research and development of new drug eugliptin tablet and Chongqing Zhifei Biological Products Co.Ltd(300122) potential heavy variety recombinant tuberculosis vaccine.
